Clinical trials: Virologically Controlled
HIV, HIV Infections
Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients
The primary purpose of this study is to evaluate the impact of changing didanosine in an effective anti-HIV regimen to tenofovir on virologic suppression.
- Trial name
- NCT00358696
- Testing
- tenofovir
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
HIV, Depression in Adults
The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV
The goal of this clinical trial is to learn if depression treatment improves insulin resistance, or how the body uses insulin to lower blood sugar, in people with HIV on HIV treatment.
- Conditions
- HIV, Depression in Adults, Insulin Resistance, Cognitive Behavior Therapy
- Trial name
- NCT07226128
- Testing
- Internet cognitive behavioral therapy (iCBT-D), Active Control (AC)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Indiana University
Chronic Hepatitis B
A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)
To evaluate the efficacy and safety of HRS9950 tablets in chronic hepatitis B patients who are virologically suppressed on nucleoside or nucleotide analogues (NAs).
- Trial name
- NCT05905458
- Testing
- HRS9950 tablets
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Hepatitis B, Chronic
A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection
This randomized, multicenter, partially double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effects of treatment with RO6864018 in…
- Trial name
- NCT02391805
- Testing
- Entecavir, RO6864018, Tenofovir
- Where
- 14 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed
The purpose of this study is to evaluate the safety, tolerability, and reactogenicity of escalating doses of JNJ-64300535 delivered via electroporation-mediated intramuscular injection in nucleos(t)ide analogs (NA)-treated…
- Trial name
- NCT03463369
- Testing
- JNJ-64300535, Nucleos(t)ide Analogs (NA)
- Where
- 14 sites in Belgium, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Janssen Sciences Ireland UC
HIV-1-Infection
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
The goal of this clinical study is to learn more about the experimental drugs lepetegravir and lenacapavir pacfosacil; to compare the combination of lepetegravir and lenacapavir pacfosacil with the current standard-of-care…
- Trial name
- WONDERS1 (NCT06544733)
- Testing
- Lepetegravir, Lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 675 people
- Sponsor
- Gilead Sciences
Depression, HIV
Depression Therapy to Improve Cardiovascular Risk in HIV
This trial will determine if depression treatment will reduce cardiovascular risk in HIV-infected patients already receiving HIV treatments.
- Trial name
- NCT02309372
- Testing
- Beating the Blues
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Indiana University
HIV-1-infection
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir…
- Trial name
- ARTISTRY-2 (NCT06333808)
- Testing
- Bictegravir, Lenacapavir, B/F/TAF
- Where
- 104 sites in United States, Argentina and 12 more
- Volunteers
- 577 people
- Sponsor
- Gilead Sciences
Hepatitis B
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and activity rules.
- Trial name
- NCT01590654
- Testing
- Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 51 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B
This randomized study will be conducted in two parts to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of subcutaneous administration of RO7062931.
- Trial name
- NCT03038113
- Testing
- RO7062931, Immune Modulator
- Where
- 19 sites in Australia, Hong Kong and 5 more
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
HIV-1 Infection
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
The primary objectives of this study are to evaluate the safety and tolerability of escalating, multiple doses of vesatolimod (formerly GS-9620) in HIV-1 infected virologically suppressed adults on antiretroviral therapy (ART)…
- Trial name
- NCT02858401
- Testing
- Vesatolimod, ARV regimen
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and…
- Trial name
- NCT05630755
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 514 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B, Chronic
A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection
The purpose of the study is to characterize the pharmacokinetic (PK) profile of cetrelimab administered subcutaneous (SC) and optionally intravenous (IV) in chronic hepatitis B (CHB) participants.
- Trial name
- NCT05242445
- Testing
- Cetrelimab
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC
HIV -1 Infection
Study of GS-0415 and How It Works in People With HIV
The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneous (SC) and…
- Trial name
- NCT07719491
- Testing
- GS-0415
- Where
- 16 sites in United States
- Volunteers
- 112 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.
- Trial name
- SOLAR (NCT04542070)
- Testing
- Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 687 people
- Sponsor
- ViiV Healthcare
Hepatitis B, Chronic
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
The purpose of this study is to evaluate the efficacy of 48-week study intervention with JNJ-73763989+JNJ-56136379+nucleos(t)ide analog (NA) regimen compared to NA alone assessed by HBsAg levels.
- Trial name
- NCT04129554
- Testing
- JNJ-73763989, JNJ-56136379, Entecavir (ETV) monohydrate
- Where
- 41 sites in Belgium, France and 5 more
- Volunteers
- 130 people
- Sponsor
- Janssen Sciences Ireland UC
HIV
Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1
The goal of this exploratory clinical trial is to evaluate the safety and tolerability of bariticinib administered at 2 mg once daily during 12 weeks in 30 people living with HIV-1 (PWH) on suppressive antiretroviral therapy…
- Trial name
- NCT07028385
- Testing
- Bariticinib 2 mg
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
HIV Infection, HAART-treated
Dolutegravir + Rilpivirine Switch Study (DORISS)
The primary objective of the study is to evaluate the capacity of Dolutegravir + Rilpivirine vs. continued triple combination HAART to maintain plasma HIV RNA ≤ 50 copies/ml throughout 24 weeks in patients with plasma HIV RNA ≤…
- Conditions
- HIV Infection, HAART-treated, Virologically Controlled
- Trial name
- DORISS (NCT02069834)
- Testing
- Arm 1 (intervention), Arm 2 (control)
- Where
- 25 sites in France
- Sponsor
- Nantes University Hospital
HIV-1
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
The purpose of this study is to assess the percent change in body weight when switching to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) (Immediate Switch Arm) compared to…
- Trial name
- DEFINE (NCT04442737)
- Testing
- D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen
- Where
- 34 sites in United States
- Volunteers
- 103 people
- Sponsor
- Janssen Scientific Affairs, LLC
HIV Infection
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)
This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose combination of doravirine and islatravir) in human immunodeficiency virus -1 (HIV-1)-infected participants virologically suppressed on a…
- Trial name
- NCT04223778
- Testing
- DOR/ISL, ART
- Where
- 78 sites in United States, Australia and 13 more
- Volunteers
- 672 people
- Sponsor
- Merck Sharp & Dohme LLC